Additionally, at 12 weeks post-infection, patients who experienced critical condition during the acute phase showed relatively lower UBE3A gene expression compared to those with severe manifestations, further supporting the critical role of enhanced UBE3A expression in influencing the severity of COVID-19 and highlighting the implications for patients with Angelman Syndrome. The gene discussed is UBE3A; the disease is COVID-19.